Primary Care Diabetes
Latest issue now available (PCD)
Diabetes guide for London
84-page PDF [NHS]
Thousands of children revealed to be suffering from diabetes
The audit, carried out by the Royal College of Paediatrics and Child Health on behalf of Sir Liam Donaldson, the Chief Medical Officer, also identified at least 328 children under 18 with type 2 diabetes, which can be associated with obesity and usually occurs much later in life (Times, UK)
Institution of Basal-Bolus Therapy at Diagnosis for Children With Type 1 Diabetes Mellitus
The institution of basal-bolus therapy with insulin glargine at the time of diagnosis of type 1 diabetes was associated with improved glycemic control, in comparison with more-conventional neutral protamine Hagedorn regimens, during the first year after diagnosis (Pediatrics)
Glucose Control by the Kidney: An Emerging Target in Diabetes
The sodium-glucose cotransporter SGLT2 (encoded by the SLC5A2 gene), which is expressed almost exclusively in proximal tubules, mediates approximately 90% of active renal glucose reabsorption. This transporter can be blocked by SGLT2 inhibitors, a class of compound that may prove effective in managing type 2 diabetes (AJKD)
ONGLYZA (Saxagliptin) Cardiovascular Profile Acceptable According to FDA Advisory Committee
The U.S. Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee determined (by a vote of 10 to 2) that the data supporting the new drug application for ONGLYZA (saxagliptin) for the treatment of adults with type 2 diabetes were sufficient to rule out unacceptable cardiovascular risk relative to comparators in the programme (AstraZeneca)
Panel: Diabetes drug seems safe, more study needed
A federal panel said Wednesday a diabetes drug from Bristol-Myers Squibb appears free from heart problems seen with similar drugs but added that long-term studies should be done after approval to confirm its safety (Washington Post, USA)
Amylin and Lilly to develop diabetes patch
Drugmakers Eli Lilly & Co. and Amylin Pharmaceuticals Inc. are developing an adhesive patch for type 2 diabetes through a partnership with Altea Therapeutics, Altea said Wednesday (Forbes)
Experience from a behavioural medicine intervention among poorly controlled adult type 1 diabetes patients
The programme proved to be feasible in terms of design and methods. However, no clear pattern was found regarding predictors or associations of improved metabolic control as the response to the intervention (Diabetes Research and Clinical Practice)
Dapagliflozin Clinical Trial Results Indicate Improvement In Key Glycemic Measures In Treatment-Naïve Type 2 Diabetes Patients
A 12-week, Phase IIb dose-ranging study showed that dapagliflozin, a novel, selective, sodium glucose co-transporter2 (SGLT2) inhibitor, produced clinically meaningful reductions across all key glycemic measures studied [glycosylated hemoglobin level (HbA1c), fasting plasma glucose (FPG), and postprandial plasma glucose (PPG)] in treatment-naïve type 2 diabetes patients, compared to placebo (PharmaLive)
Glycosmedia is also available as an App: